Product Overview
Composition
1 capsule contains:
Active ingredient:
Serennola creeping fruit extract of lipidosterol - Serenoa repens - (LSESR) - 160 mg.
Excipients:
macrogol 10000
Capsule (base and cap) No. 1 consists of:
titanium dioxide,
indigo carmine,
yellow iron oxide,
gelatin.
Active ingredient:
Serennola creeping fruit extract of lipidosterol - Serenoa repens - (LSESR) - 160 mg.
Excipients:
macrogol 10000
Capsule (base and cap) No. 1 consists of:
titanium dioxide,
indigo carmine,
yellow iron oxide,
gelatin.
pharmachologic effect
Permixon has a complex effect on the pathogenesis and symptoms of benign prostatic hyperplasia, due to the complementary effects of the constituent ingredients of this plant extract.
Permixon has antiandrogenic, anti-inflammatory, decongestant and antiproliferative effects, which are selectively manifested at the level of the prostate gland. In this case, the drug does not affect the level of sex hormones in the blood, does not cause deterioration of sexual functions, libido, potency and does not change the level of serum PSA (prostate-specific antigen).
The local antiandrogenic effect of Permixon is associated with the inhibition of the enzyme 5-alpha reductase types I and II, which is responsible for the conversion of testosterone in the prostate gland to its active form - dihydrotestosterone, and a decrease in the binding of the latter to specific receptors. A decrease in the formation of dihydrotestosterone leads to a decrease in the further growth of the prostate volume.
The local anti-inflammatory effect is due to the influence of the lipidosterol extract of creeping selenium on the main mediators of cell inflammation - it inhibits the activity of phospholipase A2, cyclooxygenase, and lipoxygenase.
Permixon during the first weeks of treatment reduces capillary permeability and vascular stasis, relieves edema and inflammation of the prostate, eliminates compression of the bladder neck and urinary tract, like alpha-blockers improves urodynamics.
The local antiproliferative effect of the drug is manifested by a decrease in the activity of growth factors (primarily epidermal and fibroblastic) and an acceleration of apoptosis of prostate cells, which is reflected in inhibition of growth and a subsequent decrease in the volume of the prostate gland.
The indicated properties of the drug contribute, on the one hand, to a reduction in pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nocturia, pain and tension when urinating, incomplete emptying of the bladder), and an increase in the volume and strength of urination.
On the other hand, Permikson contributes to the inhibition of further growth and volume of the prostate gland.
Permixon has antiandrogenic, anti-inflammatory, decongestant and antiproliferative effects, which are selectively manifested at the level of the prostate gland. In this case, the drug does not affect the level of sex hormones in the blood, does not cause deterioration of sexual functions, libido, potency and does not change the level of serum PSA (prostate-specific antigen).
The local antiandrogenic effect of Permixon is associated with the inhibition of the enzyme 5-alpha reductase types I and II, which is responsible for the conversion of testosterone in the prostate gland to its active form - dihydrotestosterone, and a decrease in the binding of the latter to specific receptors. A decrease in the formation of dihydrotestosterone leads to a decrease in the further growth of the prostate volume.
The local anti-inflammatory effect is due to the influence of the lipidosterol extract of creeping selenium on the main mediators of cell inflammation - it inhibits the activity of phospholipase A2, cyclooxygenase, and lipoxygenase.
Permixon during the first weeks of treatment reduces capillary permeability and vascular stasis, relieves edema and inflammation of the prostate, eliminates compression of the bladder neck and urinary tract, like alpha-blockers improves urodynamics.
The local antiproliferative effect of the drug is manifested by a decrease in the activity of growth factors (primarily epidermal and fibroblastic) and an acceleration of apoptosis of prostate cells, which is reflected in inhibition of growth and a subsequent decrease in the volume of the prostate gland.
The indicated properties of the drug contribute, on the one hand, to a reduction in pathological symptoms of benign prostatic hyperplasia (dysuria, pollakiuria, nocturia, pain and tension when urinating, incomplete emptying of the bladder), and an increase in the volume and strength of urination.
On the other hand, Permikson contributes to the inhibition of further growth and volume of the prostate gland.
Indications
Benign hyperplasia (adenoma) of the prostate gland of stage I and II.
Contraindications
Hypersensitivity to the drug.
Side effects
In some cases, the appearance of nausea, heartburn, gastralgia, usually occurring when taking the drug with food. In rare cases, allergic reactions.
Interaction
Compatible with the drugs most commonly used in the treatment of obstructive and inflammatory diseases of the prostate gland (antibiotics, uroantiseptics, anti-inflammatory drugs).
How to take, course of administration and dosage
Inside, with meals, 160 mg (1 capsule) 2 times a day or once in the morning.
Release form
Capsules
Storage conditions
At a temperature not exceeding 25 ° C.
Shelf life
3 years
